News and commentary from the world of gastroenterology and hepatology
— News and commentary from the world of gastroenterology and hepatology
by Ian Ingram, Managing Editor, MedPage Today
May 14, 2026
• 2 min read
Among U.S. adults with diabetes and steatotic liver disease in the All of Us cohort, new use of a GLP-1 receptor agonist was linked with a 38% to 42% lower risk of hepatic events over nearly 3 years of median follow-up. (American Journal of Gastroenterology)
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients…
Companies have “tremendous concern” about the financial viability of these medications, the president and CEO of the Business…
For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their…
GLP-1 drugs for weight loss are growing in popularity in the U.S. and across the world. Here's what some users say about their…
In trial, 82% saw weight rebound and cardiovascular health reverse after withdrawal.
A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could…
